E
Encuragen
The startup develops PEG-BHD1028, a high-affinity adiponectin receptor agonist peptide, utilizing a novel binding configuration derived from the active sequence of adiponectin receptors. This peptide aims to enhance treatment options for metabolic disorders by improving receptor activation and signaling pathways.
Traction –/10
Anyang-si, South Korea · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops PEG-BHD1028, a high-affinity adiponectin receptor agonist peptide, utilizing a novel binding configuration derived from the active sequence of adiponectin receptors. This peptide aims to enhance treatment options for metabolic disorders by improving receptor activation and signaling pathways.